Insmed (NASDAQ:INSM) Earns “Buy” Rating from HC Wainwright

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $90.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 11.03% from the company’s previous close. HC Wainwright also issued estimates for Insmed’s Q1 2025 earnings at ($1.47) EPS, Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

Several other research analysts have also recently issued reports on INSM. Guggenheim increased their price target on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Stifel Nicolaus increased their price target on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday. Finally, JPMorgan Chase & Co. increased their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.00.

Insmed Price Performance

Shares of INSM opened at $81.06 on Friday. The company has a market cap of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11. The stock has a fifty day moving average price of $74.29 and a 200 day moving average price of $73.59. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed has a 12 month low of $21.92 and a 12 month high of $84.91.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, research analysts forecast that Insmed will post -4.56 earnings per share for the current year.

Insider Activity

In other news, insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,912,553.60. This represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 532,207 shares of company stock valued at $41,400,465 over the last three months. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently modified their holdings of INSM. Jennison Associates LLC lifted its stake in Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after acquiring an additional 4,560 shares in the last quarter. Capital CS Group LLC purchased a new stake in Insmed in the 4th quarter worth about $586,000. Orion Portfolio Solutions LLC lifted its stake in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC lifted its stake in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after acquiring an additional 21,833 shares in the last quarter. Finally, TimesSquare Capital Management LLC purchased a new stake in Insmed in the 3rd quarter worth about $35,322,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.